Acadia Healthcare Company (NASDAQ: ACHC) is now facing an expanded securities class action lawsuit, with the class period extended to October 18, 2024. This development follows a New York Times report that prompted the Veterans Affairs Department to investigate allegations of Acadia holding patients longer than medically necessary. The lawsuit, initially filed on October 29, 2024, accuses Acadia of misleading investors about its business practices, including unjustified patient detention, abuse, and fraudulent billing to insurance providers.
The allegations, highlighted in a September 1, 2024, New York Times article, led to a 4% drop in Acadia's stock price. Further scrutiny arose on September 27, 2024, when Acadia disclosed receiving a federal subpoena related to its admissions and billing practices, causing a 16% stock price decline. The October 18, 2024, report on the Veterans Affairs Department's investigation into potential fraud against government health insurance programs resulted in an additional 12% stock price fall.
For investors, the lawsuit and investigations pose risks of financial losses and diminished trust in Acadia's management. The healthcare industry may also face heightened scrutiny and potential regulatory changes if the allegations are proven. This case underscores the critical need for ethical practices and transparency in patient care, particularly in the mental health sector, and may prompt stricter oversight of psychiatric facilities.
The expanded class action now includes investors who purchased Acadia stock between February 28, 2020, and October 18, 2024, with a lead plaintiff deadline of December 16, 2024. As legal proceedings continue, the Acadia case highlights the broader implications for corporate governance, investor confidence, and patient rights in the healthcare industry.
